BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Nasdaq/NYSE listing notice — BrainStorm delisted from Nasdaq; shares to trade on OTCQB from July 18

BRAINSTORM CELL THERAPEUTICS INC.

Delisting due to non-compliance with Nasdaq minimum shareholder equity rule (Rule 5550(b)(1)).
Nasdaq trading suspended at open on July 18, 2025; company received notice on July 16.
Shares approved for OTCQB quotation under same symbol BCLI starting July 18.
CEO states delisting does not alter mission; focus on NurOwn Phase 3b trial under SPA with FDA.
Company confirms no impact on business operations or ongoing R&D efforts.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

July 16, 2025, Brainstorm Cell Therapeutics Inc. (the “ Company ”) was notified by The Nasdaq Stock Market LLC (“ Nasdaq ”) that as a result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist the Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock effective at the open of trading on July 18, 2025. The Company has applied and been approved to have its common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OT

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-25-068709

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.